BackHims & Hers Health Overview
Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Target Price

See Hims & Hers Health's analyst price targets ($33) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$20.81

Average Target Price

$32.6056.7% upside

5 analysts in the last 4 months

High: $42 | Low: $26

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-24Truist Financial$3253.8% upsideOpen
2026-08-20BarclaysGlen Santangelo$3568.2% upsideOpen
2026-08-11Deutsche BankGeorge Hill$2624.9% upsideOpen
2026-08-11NeedhamRyan MacDonald$42101.8% upsideOpen
2026-08-11Morgan Stanley$2834.6% upsideOpen
2026-07-09UBS$3777.8% upsideOpen
2026-07-01Canaccord Genuity$4092.2% upsideOpen
2026-06-17Barclays$3987.4% upsideOpen
2026-06-02Leerink PartnersMichael Cherny$2520.1% upsideOpen
2026-05-26UBS$2520.1% upsideOpen
2026-05-22UBS$2310.5% upsideOpen
2026-05-12Jefferies$24.517.7% upsideOpen
2026-05-12UBS$3568.2% upsideOpen
2026-05-12Canaccord Genuity$3253.8% upsideOpen
2026-05-05Deutsche BankGeorge Hill$2520.1% upsideOpen
2026-03-10Deutsche Bank$2834.6% upsideOpen
2026-03-09NeedhamRyan MacDonald$3044.2% upsideOpen
2026-03-09Oppenheimer$12.539.9% downsideOpen
2026-02-24Barclays$2520.1% upsideOpen
2026-02-24Morgan StanleyCraig Hettenbach$210.9% upsideOpen
2026-02-24Evercore ISI$2415.3% upsideOpen
2026-02-24Truist FinancialJailendra Singh$1813.5% downsideOpen
2026-02-24Leerink Partners$17.515.9% downsideOpen
2026-02-10Deutsche BankGeorge Hill$3149% upsideOpen
2026-02-09Leerink PartnersMichael Cherny$203.9% downsideOpen
2026-02-02BTIG$60188.3% upsideOpen
2026-01-08Wolfe Research$2939.4% upsideOpen
2025-12-08Barclays$48130.7% upsideOpen
2025-12-04Leerink PartnersMichael Cherny$4197% upsideOpen
2025-11-12Morgan StanleyCraig Hettenbach$4092.2% upsideOpen
2025-11-04Seaport Global$59183.5% upsideOpen
2025-11-04Truist FinancialJailendra Singh$3777.8% upsideOpen
2025-11-04UBS$3253.8% upsideOpen
2025-11-04Leerink PartnersMichael Cherny$46121% upsideOpen
2025-06-24Truist FinancialJailendra Singh$45116.2% upsideOpen
2025-06-23UBS$3044.2% upsideOpen
2025-06-04NeedhamRyan Macdonald$65212.3% upsideOpen
2025-02-19Canaccord GenuityMaria Ripps$68226.8% upsideOpen
2024-12-02Canaccord GenuityMaria Ripps$3882.6% upsideOpen
2024-11-05Piper SandlerKorinne Wolfmeyer$210.9% upsideOpen
2024-11-05NeedhamRyan MacDonald$2834.6% upsideOpen
2024-10-29Leerink PartnersMichael Cherny$2624.9% upsideOpen
2024-10-21Bank of America SecuritiesMichael Cherny$2520.1% upsideOpen
2024-10-14Bank of America SecuritiesMichael Cherny$2310.5% upsideOpen
2024-10-14Truist FinancialJailendra Singh$2310.5% upsideOpen
2024-09-13Bank of America SecuritiesAllen Lutz$203.9% downsideOpen
2024-08-27CitigroupDaniel Grosslight$203.9% downsideOpen
2024-08-07JefferiesGlen Santangelo$1813.5% downsideOpen
2024-08-06Deutsche BankGeorge Hill$2310.5% upsideOpen
2024-05-22Canaccord GenuityMaria Ripps$2415.3% upsideOpen

Hims & Hers Health (HIMS) FAQ

Hims & Hers Health (HIMS) currently reports a target price of $33. Use the charts on this page to explore Hims & Hers Health's target price history and peer comparisons.

Analysts' average 12-month price target for Hims & Hers Health is $33, about 56.7% upside from the current share price of $20.81. That spread summarizes where covering analysts expect the stock could trade over the next year, not a guarantee. Review the individual firm targets on this page — a wide high-to-low range often means opinion is split.

Start with the current target price of $33, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Hims & Hers Health, and consider following HIMS for alerts when major investors trade the stock.

Hims & Hers Health is classified in the Consumer Staples sector. On target price, it currently shows $33. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Consumer Staples are usually more informative than comparing HIMS with unrelated industries.